Official announcements, corporate milestones, and platform updates from NanoKar Therapeutics. For media inquiries, please contact us directly.
NanoKar Therapeutics has been accepted into the Innosphere Ventures accelerator program in Fort Collins, Colorado. The program provides mentorship, investor access, and business development support as NanoKar advances its ITAM optimization platform for CAR-T cell therapy toward strategic partnerships.
Read the full releaseNanoKar Therapeutics has been awarded funding from the University of Utah Launchpad Seed Fund to advance its ITAM optimization platform for CAR-T cell therapy. The capital will support translational validation data, including CAR-T persistence and activity in solid tumor models, and help prepare the platform for evaluation by potential development partners.
Read the full releaseNanoKar Therapeutics has formally appointed Craig Mosman, J.D., as Chief Executive Officer. Mosman will lead the company’s partnership strategy and translational data priorities as it advances the ITAM optimization platform developed in the Bettini Lab at the University of Utah toward partner-ready commercialization.
Read the full releaseNanoKar Therapeutics has secured an exclusive global license from the University of Utah Technology Licensing Office for a novel CAR-T cell engineering platform developed by Matthew Bettini, Ph.D. The licensed ITAM optimization technology is designed to tune intracellular CAR signaling to improve persistence, reduce toxicity, and expand efficacy in solid tumors.
Read the full releaseFor press and partnership inquiries, please reach out directly.
This website may contain forward-looking statements regarding NanoKar Therapeutics, Inc., including statements about the company’s research and development programs, the potential of its ITAM optimization platform, anticipated preclinical and clinical milestones, intellectual property, and plans for partnerships, financing, and commercialization. These statements are based on current expectations and assumptions and are subject to risks and uncertainties. Actual results may differ materially from those expressed or implied. NanoKar Therapeutics undertakes no obligation to update any forward-looking statement except as required by law. Nothing on this website constitutes an offer to sell or a solicitation of an offer to buy any securities.